Affordable Access

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Authors
  • Miller, V
  • Stürmer, M
  • Staszewski, S
  • Gröschel, B
  • Hertogs, K
  • de Béthune, M P
  • Pauwels, R
  • Harrigan, P R
  • Bloor, S
  • Kemp, S D
  • Larder, B A
Type
Published Article
Journal
AIDS
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
May 07, 1998
Volume
12
Issue
7
Pages
705–712
Identifiers
PMID: 9619801
Source
Medline
License
Unknown

Abstract

Cross-resistance was not commonly observed in this lamivudine-treated cohort. M184V per se is not expected to compromise subsequent treatment with NRTI such as didanosine-stavudine or combinations containing abacavir.

Report this publication

Statistics

Seen <100 times